Atezolizumab (Tecentriq®)
Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK‑positive tumour mutations should also have received targeted therapy before receiving atezolizumab.
| NCPE Rapid Review Process | Complete |
| Rapid Review Comissioned | 08/08/2017 |
| Rapid Review Completed | 09/10/2017 |
| Outcome | Full pharmacoeconomic assessment recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 11/10/2017 |
| Pre-submission consultation with Applicant | 28/11/2017 |
| Submission received from Applicant | 08/01/2018 |
| Preliminary review sent to Applicant | 29/05/2018 |
| NCPE assessment re-commenced | 15/06/2018 |
| Preliminary review II sent to Applicant | 31/07/2018 |
| NCPE assessment re-commenced | 21/08/2018 |
| Factual accuracy sent to Applicant | 04/09/2018 |
| NCPE assessment re-commenced | 19/09/2018 |
| NCPE assessment completed | 20/09/2018 |
| NCPE assessment outcome | The NCPE recommends that atezolizumab not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013. |
The HSE has approved reimbursement following confidential price negotiations; March 2019